Le Registre des lobbyistes
Médicaments novateurs Canada / Innovative Medicines Canada
Objets | Détails | Catégories |
---|---|---|
Santé, Commerce intérieur, Commerce international, Justice et application des lois
|
Anti-Counterfeit Trade Agreement (ACTA) as it concerns counterfeit drugs
|
Politique ou Programme
|
Développement économique, Marchés publics, Santé, Développement international, Relations internationales, Commerce international, Développement régional, Recherche et développement
|
Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease
|
Politique ou Programme
|
Questions touchant les consommateurs, Santé, Industrie, Justice et application des lois
|
Canada's Food and Consumer Safety Action Plan as it relates to the regulation and protection of biopharmaceutical products
|
Proposition législative, Projet de loi ou résolution
|
Santé, Propriété intellectuelle, Relations internationales, Commerce international
|
Canada-United States Regulatory Cooperation Council (RCC) initiatives related to the regulation of biopharmaceutical products
|
Politique ou Programme
|
Environnement, Santé, Sciences et technologies
|
Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies
|
Règlement, Proposition législative, Projet de loi ou résolution
|
Développement économique, Santé, Propriété intellectuelle, Recherche et développement, Sciences et technologies
|
Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships
|
Politique ou Programme
|
Questions touchant les consommateurs, Relations fédérales-provinciales, Propriété intellectuelle, Sciences et technologies
|
Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework
|
Politique ou Programme
|
Relations fédérales-provinciales, Santé, Propriété intellectuelle, Sciences et technologies
|
Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)
|
Politique ou Programme
|
Questions touchant les consommateurs, Santé, Propriété intellectuelle, Recherche et développement
|
Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
|
Règlement
|
Santé, Propriété intellectuelle, Relations internationales, Commerce international, Impôts et finances
|
Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals
|
Proposition législative, Projet de loi ou résolution, Règlement
|
Santé, Propriété intellectuelle, Relations internationales, Commerce international, Impôts et finances
|
Free trade treaty agreement as they relate to The Canada-United States-Mexico Agreement (CUSMA) and free trade negotiations as it relates to India, the European Union, Japan, MERCOSUR and the Trans-Pacific Partnership
|
Politique ou Programme
|
Questions touchant les consommateurs, Santé, Industrie, Propriété intellectuelle, Recherche et développement
|
Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry
|
Règlement
|
Santé, Industrie, Propriété intellectuelle
|
New Substances Notification Regulations as it relates to the biopharmaceutical industry
|
Règlement
|
Santé, Industrie, Propriété intellectuelle, Commerce international, Recherche et développement, Impôts et finances
|
Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
|
Proposition législative, Projet de loi ou résolution
|
Santé, Propriété intellectuelle, Recherche et développement, Impôts et finances
|
Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
|
Règlement
|
Santé, Propriété intellectuelle, Développement international, Relations internationales, Commerce international, Impôts et finances
|
Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive
|
Règlement
|
Santé, Industrie, Propriété intellectuelle, Développement international, Relations internationales, Commerce international, Recherche et développement
|
Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products
|
Règlement
|
Questions touchant les consommateurs, Santé, Industrie, Propriété intellectuelle, Développement international, Relations internationales, Commerce international, Impôts et finances
|
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
|
Politique ou Programme
|
Questions constitutionnelles, Questions touchant les consommateurs, Relations fédérales-provinciales, Marchés publics, Santé, Industrie
|
Proposed pharmacare legislation related to any future national pharmacare program
|
Proposition législative, Projet de loi ou résolution
|
Développement économique, Propriété intellectuelle, Recherche et développement, Sciences et technologies, Impôts et finances
|
Scientific Research and Experimental Development (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits
|
Politique ou Programme
|
Santé, Industrie
|
Smart Regulations as it relates to the biopharmaceutical industry
|
Règlement
|
Santé, Industrie, Propriété intellectuelle, Ressources naturelles, Sciences et technologies
|
Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations
|
Politique ou Programme
|
Santé, Industrie, Ressources naturelles, Sciences et technologies
|
The government's Science and Technology strategy as it relates to the biopharmaceutical industry
|
Politique ou Programme
|
Santé, Industrie, Propriété intellectuelle, Développement international, Relations internationales, Commerce international
|
World Health Organization (WHO) issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernmental Working Group (IGWG)
World Intellectual Property Organization (WIPO) issues concerning the protection of and access to intellectual property
|
Politique ou Programme
|
Santé, Industrie, Propriété intellectuelle, Développement international, Relations internationales, Commerce international
|
World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility"
|
Politique ou Programme
|